Alkermes Quarterly Cash Flow Statement
NASDAQ: ALKSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alkermes free cash flow
In the quarter ended Jun 30, 2026, Alkermes generated $145.2 million of operating cash flow and spent $8.1 million on capital expenditures. That left free cash flow of $137.0 million, a free-cash-flow margin of 27.6% of revenue. Free cash flow was down 0.1% from the prior year's $137.2 million.
Summary generated from market data by MetaCap's automated system. Methodology
Alkermes cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 501.00K | -66.48M | 49.34M | 82.76M | 87.10M | 22.46M | 146.50M | 92.38M | 91.36M | 36.83M | 112.78M | 47.76M |
| Net Income growth (YoY) | -99.42% | -395.94% | -66.32% | -10.41% | -4.66% | -39.00% | +29.90% | +93.44% | -61.46% | — | — | — |
| Depreciation & Amortization | 30.28M | 19.43M | 3.85M | 8.08M | 7.82M | 7.42M | 6.85M | 6.97M | 6.66M | 8.06M | 18.54M | 18.66M |
| Stock-Based Compensation | 31.14M | 36.33M | 26.27M | 24.66M | 24.97M | 22.81M | 20.75M | 22.53M | 20.60M | 32.76M | 25.84M | 23.91M |
| Change in Working Capital | 1.90M | -144.23M | 93.14M | -26.83M | 9.46M | 65.60M | 18.83M | -75.00M | -11.09M | -34.77M | 10.09M | 177.00K |
| Operating Cash Flow | 145.18M | -165.74M | 170.07M | 101.67M | 150.20M | 98.81M | 190.40M | 81.59M | 146.03M | 21.11M | 107.24M | 99.71M |
| Capital Expenditures | -8.15M | -4.09M | 20.00K | -17.31M | -13.02M | -10.11M | -9.77M | -8.26M | -7.11M | -8.34M | -17.03M | -14.45M |
| Investing Cash Flow | -2.41M | -2.08B | 322.35M | -6.74M | -29.21M | 9.10M | -13.88M | -109.33M | 51.85M | -39.95M | -20.98M | -119.36M |
| Share Repurchases | 0 | -27.70M | — | — | — | — | -1.00K | -115.59M | — | — | — | — |
| Debt Issued | 0 | 1.51B | — | — | — | — | — | — | — | — | — | — |
| Debt Repaid | — | — | — | — | — | — | 0 | -750.00K | -750.00K | -750.00K | -750.00K | -750.00K |
| Financing Cash Flow | 17.20M | 1.47B | 10.91M | 315.00K | 405.00K | 747.00K | -281.67M | -111.11M | -83.48M | -17.87M | -276.50M | 1.57M |
| Net Change in Cash | 159.98M | -768.23M | 503.33M | 95.25M | 121.39M | 108.66M | -105.15M | -138.86M | 114.40M | -36.72M | -190.24M | -18.08M |
| Free Cash Flow | 137.04M | -169.83M | 170.09M | 84.36M | 137.19M | 88.70M | 180.62M | 73.33M | 138.92M | 12.77M | 90.21M | 85.25M |
This table shows 12 quarterly periods of Alkermes's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ALKS's reporting calendar. What is a cash flow statement?